Recursion Pharmaceuticals (RXRX) News Today $9.65 -0.70 (-6.72%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?February 21 at 10:56 AM | msn.comSudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.February 21 at 8:02 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.5% - Time to Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 6.5% - Here's What HappenedFebruary 20 at 12:32 PM | marketbeat.comWhy Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025February 19 at 11:32 PM | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 23.9% - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 23.9% - What's Next?February 19 at 6:42 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 10.7% Higher - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 10.7% Higher - What's Next?February 19 at 2:37 PM | marketbeat.comTop Biotech Stocks To Follow Today - February 19thRecursion Pharmaceuticals, Thermo Fisher Scientific, Danaher, AbbVie, Moderna, IQVIA, and Charles River Laboratories International are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies involved in the research, developmentFebruary 19 at 2:11 PM | marketbeat.comWhy Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)February 19 at 9:41 AM | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5% - Time to Buy?February 18 at 11:38 PM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Time to Buy?February 18 at 10:14 PM | marketbeat.comAltitude Lab Startups Raise $154M in CapitalFebruary 18 at 11:00 AM | globenewswire.comRecursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on TuesdayRecursion Pharmaceuticals (NASDAQ:RXRX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 5:16 AM | marketbeat.comWhy Recursion Pharmaceuticals, Inc. (RXRX) Soared Last WeekFebruary 17, 2025 | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 23.9% - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 23.9% - Still a Buy?February 17, 2025 | marketbeat.comBaillie Gifford & Co. Sells 375,812 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Baillie Gifford & Co. trimmed its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,864,058 shares of the company's stock after selling 375,81February 17, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's WhyFebruary 16, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Mirae Asset Global Investments Co. Ltd. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 85.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,721 shares of the company's stock after selling 74,818 shares durinFebruary 15, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% Higher - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.6% - Here's What HappenedFebruary 14, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Is Soaring TodayFebruary 14, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?February 14, 2025 | marketbeat.comRecursion Pharmaceuticals Needs A Clinical Breakthrough To Pique InterestFebruary 14, 2025 | seekingalpha.comBiotechs on the Brink: 2 Stocks With Huge Potential (RXRX)BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.February 14, 2025 | marketbeat.comRecursion: CDK7 Inhibitor Differentiation Is Initially Paying OffFebruary 13, 2025 | seekingalpha.comRecursion Pharmaceuticals files automatic mixed securities shelfFebruary 12, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.6% - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 8.6% - Time to Buy?February 12, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Lowers Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 8.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,980,601 shares of the company's stock after selling 786,127 shares dFebruary 10, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Still a Buy?February 8, 2025 | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday?February 7, 2025 | msn.comRecursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors purchased 23,699 call options on the stock. This is an increase of 51% compared to the average daily volume of 15,658 call options.February 7, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Recursion Pharmaceuticals (NASDAQ:RXRX)Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday.February 6, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume - Here's WhyFebruary 6, 2025 | marketbeat.comRecursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading on Thursday. Investors bought 23,699 call options on the company. This is an increase of 51% compared to the average volume of 15,658 call options.February 6, 2025 | marketbeat.comRecursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke ConferenceFebruary 5, 2025 | globenewswire.comSG Americas Securities LLC Lowers Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)SG Americas Securities LLC trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 44.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,343 shares of the coFebruary 5, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 9% Higher - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 9% - Here's WhyFebruary 1, 2025 | marketbeat.com3 Monster Stocks to Hold for the Next 10 YearsFebruary 1, 2025 | fool.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6% - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6% - Here's WhyJanuary 31, 2025 | marketbeat.comInstitute for Wealth Management LLC. Acquires Shares of 580,997 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Institute for Wealth Management LLC. bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 580,997 shares of the company's stock, valued at approximatelyJanuary 31, 2025 | marketbeat.comInstitutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term lossesJanuary 31, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 9% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9% - Here's What HappenedJanuary 30, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.6% - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6% - Here's What HappenedJanuary 29, 2025 | marketbeat.comIs Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025?January 29, 2025 | insidermonkey.comAI Pharma: 2 Paths to AI-Powered Drug InvestmentAI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.January 28, 2025 | marketbeat.comAccel Wealth Management Takes $310,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Accel Wealth Management bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 45,800 shares of the company's stock, valuJanuary 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.4% Higher - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.4% Higher - Here's What HappenedJanuary 26, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's What HappenedJanuary 25, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 6.4% - Should You Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.4% Higher - Time to Buy?January 24, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's WhyRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?January 24, 2025 | marketbeat.comFY2024 Earnings Estimate for RXRX Issued By Leerink PartnrsRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Leerink Partnrs dropped their FY2024 EPS estimates for Recursion Pharmaceuticals in a report released on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($1.January 24, 2025 | marketbeat.comInvestors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 33,531 call options on the company. This represents an increase of 180% compared to the typical daily volume of 11,957 call options.January 23, 2025 | marketbeat.com Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.650.60▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼208▲RXRX Articles Average Week Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
